Home » Flora Chung

Flora Chung

Senior Analyst

Flora Chung is a Senior Analyst at CBPartners.

Connect with Flora Chung



Published Articles

What Market Access Opportunities Exist for Oncology Products in China? An Analysis of Oncology Product Inclusion in the 2020 NRDL

Fourteen oncology drugs were successfully negotiated and included in the 2020 NRDL. As the new prices became effective from March 01, 2021, several key features and trends have been observed.